{
    "2021-01-19": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade",
                "features": {
                    "keywords": [
                        "catalysts",
                        "pipeline updates",
                        "Mizuho",
                        "upgrade"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Eli Lilly Stock Is Still Pricey. Why It Might Be a Buy.",
                "features": {
                    "keywords": [
                        "pricey",
                        "buy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies",
                "features": {
                    "keywords": [
                        "collaboration",
                        "Merus NV",
                        "T-Cell",
                        "bispecific antibodies"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}